{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:09:59Z","timestamp":1790755799006,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Janssen Research and Development, Janssen Pharmaceutica N.V."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.neuropharm.2012.06.040","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T22:14:10Z","timestamp":1341267250000},"page":"197-204","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study"],"prefix":"10.1016","volume":"64","author":[{"given":"Georg","family":"Winterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Gallinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Brinkmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Thuerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyna","family":"Favis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique A.","family":"Franc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivi","family":"Ouwerkerk-Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes R.","family":"Streffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.040_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0006-3223(92)90073-9","article-title":"Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics","volume":"32","author":"Adler","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib2","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1176\/ajp.150.12.1856","article-title":"Normalization of auditory physiology by cigarette smoking in schizophrenic patients","volume":"150","author":"Adler","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.schbul.a033320","article-title":"Schizophrenia, sensory gating, and nicotinic receptors","volume":"24","author":"Adler","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-12-381264-3.00005-9","article-title":"Positive and negative modulation of nicotinic receptors","volume":"80","author":"Arias","year":"2010","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neubiorev.2011.06.007","article-title":"Smoking, quitting, and psychiatric disease: a review","volume":"36","author":"Aubin","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1476-5381.1995.tb13248.x","article-title":"Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine","volume":"114","author":"Benwell","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1073\/pnas.89.4.1261","article-title":"Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain","volume":"89","author":"Bertrand","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib8","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1523\/JNEUROSCI.2444-07.2007","article-title":"Broad spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1\/2 and CREB phosphorylation pathways","volume":"27","author":"Bitner","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-004-1848-0","article-title":"Preattentional and attentional cognitive deficits as targets for treating schizophrenia","volume":"174","author":"Braff","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1369-1600.2010.00302.x","article-title":"P50 sensory gating and smoking in the general population","volume":"16","author":"Brinkmeyer","year":"2011","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1471-4159.2010.06845.x","article-title":"Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain","volume":"114","author":"Christensen","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib12","first-page":"47","article-title":"Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction","volume":"9","author":"Cincotta","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0361-9230(90)90222-L","article-title":"Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors","volume":"25","author":"Collins","year":"1990","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ajmg.a.33917","article-title":"Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome","volume":"155A","author":"Cubells","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(00)00003-0","article-title":"Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas","volume":"393","author":"Dani","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1074\/jbc.M110.180067","article-title":"Function of partially duplicated human \u03b177 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response","volume":"286","author":"de Lucas-Cerrillo","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/wnf.0b013e31806462ba","article-title":"First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy","volume":"31","author":"Deutsch","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14622200601078277","article-title":"Sensitization to nicotine: how the animal literature might inform future human research","volume":"9","author":"DiFranza","year":"2007","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(98)00075-9","article-title":"P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention","volume":"33","author":"Erwin","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib20","series-title":"The Structured Clinical Interview for DCM-IV Axis I Disorders Research Version (SCID-1)","author":"First","year":"1996"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","article-title":"Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia","volume":"38","author":"Freedman","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.94.2.587","article-title":"Linkage of a neuropsychological deficit in schizophrenia to a chromosome 15 locus","volume":"94","author":"Freedman","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1096-8628(20010108)105:1<20::AID-AJMG1047>3.0.CO;2-C","article-title":"Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7- nicotinic acetylcholine receptor subunit gene (CHRNA7)","volume":"105","author":"Freedman","year":"2001","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1176\/appi.ajp.2008.07071135","article-title":"Initial phase 2 trial of a nicotinic agonist in schizophrenia","volume":"165","author":"Freedman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1469-8986.2007.00524.x","article-title":"Range of sensory gating values and test-retest reliability in normal subjects","volume":"44","author":"Fuerst","year":"2007","journal-title":"Psychophysiology"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib26","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1073\/pnas.1017975108","article-title":"Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site","volume":"108","author":"Gill","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.psychres.2004.09.009","article-title":"Auditory P3 indexes personality traits and cognitive function in healthy men and women","volume":"133","author":"Gurrera","year":"2005","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2174\/138161210790361434","article-title":"Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia","volume":"16","author":"Haj\u00f3s","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1214\/009053604000000887","article-title":"Optimal and efficient crossover designs for comparing test treatments with a control treatment","volume":"33","author":"Hedayat","year":"2005","journal-title":"Ann. Statist."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ng.292","article-title":"15q13.3 microdeletions increase risk of idiopathic generalized epilepsy","volume":"41","author":"Helbig","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature07239","article-title":"Rare chromosomal deletions and duplications increase risk of schizophrenia","volume":"455","author":"International Schizophrenia Consortium","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/138161211795049561","article-title":"\u03b17 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia","volume":"17","author":"Ishikawa","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2463","article-title":"Neurophysiological biomarkers for drug development in schizophrenia","volume":"7","author":"Javitt","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1469-8986.1986.tb00649.x","article-title":"A\u00a0triarchic model of P300 amplitude","volume":"23","author":"Johnson","year":"1986","journal-title":"Psychophysiology"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2011.09.167","article-title":"Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP","volume":"671","author":"Kroker","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biopsych.2006.03.054","article-title":"Genetics of chromosome 15q13-q14 in schizophrenia","volume":"60","author":"Leonard","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/(SICI)1096-8628(19980710)81:4<308::AID-AJMG6>3.0.CO;2-P","article-title":"Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH genetics initiative","volume":"81","author":"Leonard","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0014-2999(00)00035-2","article-title":"Smoking and schizophrenia: abnormal nicotinic receptor expression","volume":"393","author":"Leonard","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib39","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.59.12.1085","article-title":"Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia","volume":"59","author":"Leonard","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1300\/J374v03n03_05","article-title":"Smoking, genetics and schizophrenia: evidence for self medication","volume":"3","author":"Leonard","year":"2007","journal-title":"J.\u00a0Dual Diagn."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib41","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1038\/npp.2008.1","article-title":"Nicotinic acetylcholine receptors and modulation of learning in 4- and 27-month-old rabbits","volume":"33","author":"Li","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1176\/appi.ajp.2008.08050769","article-title":"Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry","volume":"165","author":"Lieberman","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00702-011-0743-1","article-title":"Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms","volume":"119","author":"Luckhaus","year":"2012","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/jpet.109.151886","article-title":"In\u00a0vitro pharmacological characterization of a novel allosteric modulator of \u03b17 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile","volume":"330","author":"Malysz","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nature08494","article-title":"Finding the missing heritability of complex diseases","volume":"461","author":"Manolio","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib46","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1046\/j.1471-4159.2002.00910.x","article-title":"Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice","volume":"81","author":"Marks","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/jmg.2008.059907","article-title":"Microdeletion\/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders","volume":"46","author":"Miller","year":"2009","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijpsycho.2010.06.002","article-title":"The P300 event-related potential and smoking\u2013a population-based case-control study","volume":"77","author":"Mobascher","year":"2010","journal-title":"Int. J. Psychophysiol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib49","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hipo.20572","article-title":"Galantamine enhancement of long-term potentiation is mediated by calcium\/calmodulin-dependent protein kinase II and protein kinase C activation","volume":"19","author":"Moriguchi","year":"2009","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.neuroimage.2011.06.045","article-title":"Ketamine effects on brain function\u2013simultaneous fMRI\/EEG during a visual oddball task","volume":"58","author":"Musso","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0920-9964(91)90007-E","article-title":"Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave","volume":"4","author":"Nagamoto","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000026553","article-title":"Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol","volume":"39","author":"Nagamoto","year":"1999","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib53","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.bcp.2007.07.015","article-title":"Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men","volume":"74","author":"Olincy","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","article-title":"Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia","volume":"63","author":"Olincy","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.108.150151","article-title":"Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine","volume":"329","author":"Papke","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.npp.1301188","article-title":"SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia","volume":"32","author":"Pichat","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/biomet\/74.2.321","article-title":"Crossover designs for comparing treatments with a control","volume":"74","author":"Pigeon","year":"1987","journal-title":"Biometrika"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bcp.2009.04.031","article-title":"Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences","volume":"78","author":"Poorthuis","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1467-9450.00168","article-title":"Does P3 reflect attentional or memory performances, or cognition more generally?","volume":"41","author":"Portin","year":"2000","journal-title":"Scand. J. Psychol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1118051109","article-title":"Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating","author":"Quednow","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib61","doi-asserted-by":"crossref","DOI":"10.2174\/138945012800398874","article-title":"Alpha7 nicotinic acetylcholine receptors: an old actor for new different roles","author":"Russo","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib62","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.gde.2009.04.010","article-title":"Common vs. rare allele hypotheses for complex diseases","volume":"19","author":"Schork","year":"2009","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/ng.93","article-title":"A\u00a0recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures","volume":"40","author":"Sharp","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib64","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00213-002-1285-x","article-title":"Clozapine improves deficient inhibitory auditory processing in DBA\/2 mice, via a nicotinic cholinergic mechanism","volume":"165","author":"Simosky","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature07229","article-title":"Large recurrent microdeletions associated with schizophrenia","volume":"455","author":"Stefansson","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib66","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0091-3057(96)00466-2","article-title":"Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models","volume":"57","author":"Stevens","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib67","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/npp.2010.227","article-title":"Nicotinergic impact on focal and non-focal neuroplasticity induced by non-invasive brain stimulation in non-smoking humans","volume":"36","author":"Thirugnanasambandam","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib68","article-title":"The alpha7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets","author":"Thomsen","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib69","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/138161210790170094","article-title":"Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology","volume":"16","author":"Thomsen","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib70","doi-asserted-by":"crossref","first-page":"e27014","DOI":"10.1371\/journal.pone.0027014","article-title":"Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats","volume":"6","author":"Thomsen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0920-9964(94)90067-1","article-title":"Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings","volume":"12","author":"Waldo","year":"1994","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpsycho.2005.03.024","article-title":"P50 sensory gating: impact of high vs. low schizotypal personality and smoking status","volume":"60","author":"Wan","year":"2006","journal-title":"Int. J. Psychophysiol."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.psychres.2006.01.020","article-title":"Early and late auditory sensory gating: moderating influences from schizotypal personality, tobacco smoking status, and acute smoking","volume":"151","author":"Wan","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib74","doi-asserted-by":"crossref","DOI":"10.1162\/jocn_a_00236","article-title":"Nicotine effects on brain function during a visual oddball task: a comparison between conventional and EEG-informed fMRI analysis","author":"Warbrick","year":"2012","journal-title":"J.\u00a0Cogn. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.06.040_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1176\/appi.ajp.2011.11060822","article-title":"Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3","volume":"169","author":"Williams","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib76","series-title":"Neuropsychiatric Biomarkers, Endophenotypes, and Genes: Promises, Advances and Challenges","first-page":"57","article-title":"Translational medicine: functional biomarkers for drug development of \u201ccognitive enhancers\u201d in schizophrenia","volume":"vol. I","author":"Winterer","year":"2009"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib77","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0b013e3283366643","article-title":"Why do patients with schizophrenia smoke?","volume":"23","author":"Winterer","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib78","series-title":"Schizophrenia","article-title":"Electrophysiology of schizophrenia","author":"Winterer","year":"2011"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib79","doi-asserted-by":"crossref","first-page":"14686","DOI":"10.1073\/pnas.0804372105","article-title":"Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site","volume":"105","author":"Young","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neuropharm.2012.06.040_bib80","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/14622200802443569","article-title":"Tobacco use and cessation in psychiatric disorders: national institute of mental health report","volume":"10","author":"Ziedonis","year":"2008","journal-title":"Nicotine Tob. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:36:20Z","timestamp":1714124180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":80,"alternative-id":["S0028390812002985"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.040","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}